• Home
  • About Journal
    Journal Introduction
    Editorial Board
    Youth Editorial Board
    Cooperating Institutions
    Editorial Department
  • Submission Guidelines
  • Policies & Statements
    Ethical Guidelines for Publication
    Academic Misconduct Statement
    Open Access (OA) Statement
    AIGC Use Statement
  • Journal Subscription
  • Download Center
  • 中文版
Cite this article:
.近年来,社区获得性肺炎成为最为常见的肺部感染,发病群体极为广泛,造成严重的健康威胁。本文对抗菌药物细菌耐药性、药物递送系统(DDS)在肺部感染治疗方面的优势和研究难点等研究进行归纳和总结,简要介绍了抗菌药物在肺部治疗的现状,针对肺部感染的药物递送,特别是针对铜绿假单胞菌(PA)感染,讨论了目前肺部递送抗菌药物载体的研究进展及DDS与肺部生物屏障的相互作用,以期为解决抗菌药物治疗方面面临的重大问题和克服肺部生物学屏障、提高药物在感染病灶的生物利用度提供一种新的思路。[J].Journal Of Pharmaceutical Research,2020,39(11):659-665[Click to copy]
【Print this page】      【Download PDF Full Text】   【View/Add Comment】  【Download reader】  【 Close 】
←Previous|Next→ Archive    Advanced Search
This article has been viewed: 2774times   Download 2368次 QR Code for this article
Scan with your phone!
肺部药物递送系统在肺部感染治疗领域的现状和进展
李楠,刘畅,刘洪斌
Font:Larger+|Default|Smaller-
(天津市医药科学研究所,天津 300020)
摘要:
Status and progress of pulmonary drug delivery systems in the treatment of lung infections
关键词:  抗菌药物  细菌耐药  铜绿假单胞菌  吸入制剂  药物递送系统
DOI:10.13506/j.cnki.jpr.2020.11.010
基金项目:国家自然科学基金(No.81903565);天津市自然科学基金项目(No.18JCQNJC13500)
Publication Date:November 25, 2020
近年来,社区获得性肺炎成为最为常见的肺部感染,发病群体极为广泛,造成严重的健康威胁。本文对抗菌药物细菌耐药性、药物递送系统(DDS)在肺部感染治疗方面的优势和研究难点等研究进行归纳和总结,简要介绍了抗菌药物在肺部治疗的现状,针对肺部感染的药物递送,特别是针对铜绿假单胞菌(PA)感染,讨论了目前肺部递送抗菌药物载体的研究进展及DDS与肺部生物屏障的相互作用,以期为解决抗菌药物治疗方面面临的重大问题和克服肺部生物学屏障、提高药物在感染病灶的生物利用度提供一种新的思路。
()
Abstract:
In recent years,community-acquired pneumonia has become the most common lung infection, with a very wide range of disease groups, posing a serious health threat. This article summarizes studies on antibacterial drug resistance, drug delivery system advantages and research difficulties in the treatment of lung infections, and briefly introduces the current status of antibacterial drugs in lung treatment.Drug delivery for lung infections, Especially for Pseudomonas aeruginosa (PA) infection, the current research progress of antibacterial drug delivery in the lungs and the interaction between DDS and the biological barrier of the lungs are discussed in order to solve the major problems faced by antibacterial drugs and overcome the lung It can provide a new way of thinking about the biological barrier and improve the bioavailability of drugs in infected lesions.
Key words:  Antibacterial drugs  Bacterial resistance  Pseudomonas aeruginosa  Inhaled preparation  Drug delivery system
Today's Visits:527    Total Visits:2383269
Website copyright:Editorial Board of Journal of Pharmaceutical Research     鲁ICP备17018036号-3     鲁公网安备 37010202001351号
Sponsored by:Shandong Institute for Food and Drug Control Shandong Pharmaceutical Association Address:No.2749 Xinluo Street,High-Tech Zone,Jinan,P.R.China Postcode:250101
Telephone Number:0531-81216586 Email :yaoxueyanjiu@163.com;yaoxueyanjiu@126.com
Technical Support:Beijing Qinyun Technology Co., Ltd.